Encouraging results with sintilimab combination therapy in EGFR-mutated non-squamous NSCLC
In the first interim analysis of the ORIENT-31 trial, progression-free survival was slightly improved in patients who progressed after EGFR TKI, but mature results are needed to confirm whether combination therapy represents a new therapeutic option in this setting
Should renal cell carcinomas be managed differently in Asia?
The Pan-Asian adaptation of the ESMO guidelines introduces some changes to the standard of care in Europe, including diagnostic tests and the use of cytoreductive nephrectomy
Genetics and availability of treatments influence the management of head and neck cancer in Asia
The Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines is presented at the ESMO Asia Virtual Oncology Week 2021
Tailoring the management of localised colon cancer to the Asian population
Risk assessment and alternative fluoropyrimidine regimens are the main changes in the Pan-Asian adapted ESMO Clinical Practice Guidelines, reinforcing ESMO’s commitment in the region
IMpower010 and DESTINY-Lung01 are likely to change clinical practice in Asia
However, regulatory and financial issues will shape when and where this happens
What is the impact of first-line nivolumab on subsequent therapy choices for metastatic gastric cancer?
Knock-on effects of early immune checkpoint inhibitor use stimulate consideration of alternative approaches for further treatment lines
Some practice-changing results in breast cancer are perceived differently in low-resourced countries
Cost, limited drug availability and lack of diagnostic testing facilities are hurdles to adopting practice-changing recommendations in some Asian countries
New insights into the mechanism of acquired resistance to KRAS G12C inhibitors
Sequencing data suggest that non-G12C KRAS mutations could mediate intrinsic resistance to treatments in non-small-cell lung cancer, but functional confirmation is required
Study sheds light on lung adenocarcinoma-to-squamous transdifferentiation mechanism
AKT and EZH2 are identified as potential therapeutic targets to limit acquired resistance to osimertinib in patients with EGFR-mutated tumours of the lung
Next-generation sequencing of circulating tumour DNA can optimise clinical trial recruitment
Molecular pre-screening identified targetable alterations in patients with unknown genomic drivers